Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation
NCT04694092Unknown
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of landiolol in Atrial fibrillation (AFib) and Acute Heart Failure (AHF) (2 arms), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoints: Heart rate control at 2 hours and Change in patient-reported symptoms at 2 hours. Status: unknown.
02
Drugs
landiolol
03
Conditions
Atrial fibrillation (AFib)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT04694092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04694092.